secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196465
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN
--------------------------------------------------------------------------------

- Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.
- Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.
- Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.
- All VALIANT completers enrolled in long-term extension study VALE.
- Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/0001193125-24-196465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524196465/d848612d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer